Clinical trial
A Long Term Safety Study With Atrasentan
NCT00127478 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00127478 |
|---|---|
| Title | A Long Term Safety Study With Atrasentan |
| Official title | A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Atrasentan |
| Enrollment | 166 |
| Start date | Jul 1, 2001 |
| Completion | Jun 1, 2007 |
| First posted | Aug 8, 2005 |
| Last update posted | Nov 29, 2007 |
| Countries | Canada, France, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: